Dinja T. Kruger

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Marcelo Sobral‐Leite, Izhar Salomon, Mark Opdam et al. · Breast Cancer Research · 2019 · 131 citations · Full text

Medicine, Immunology, Oncology +15

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer

Dinja T. Kruger, Xanthippi Alexi, Mark Opdam et al. · International Journal of Cancer · 2019 · 33 citations · Full text

Medicine, Cancer Biology, Oncology +15

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer

Jinhyuk Bhin, Julia Yemelyanenko, Xue Chao et al. · The Journal of Experimental Medicine · 2023 · 28 citations · Full text

Medicine, Cancer Biology, Oncology +17

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences

Dinja T. Kruger, Karin Beelen, Mark Opdam et al. · British Journal of Cancer · 2018 · 23 citations · Full text

Life Sciences, Molecular Biology, Oncology +15

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane

Dinja T. Kruger, Maurice P.H.M. Jansen, Inge R. Konings et al. · Molecular Oncology · 2019 · 20 citations · Full text

Medicine, Molecular Medicine, Oncology +17